PRS 343

Drug Profile

PRS 343

Alternative Names: HER2/41BB bispecific; PRS-343

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pieris Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Lipocalins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action CD137 antigen agonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 09 Aug 2018 Pieris Pharmaceuticals plans a clinical trial for Cancer (Combination therapy with atezolizumab) in the second half of 2018
  • 16 Feb 2018 Pieris Pharmaceuticals plans clinical trials in Cancer (Combination therapy)
  • 02 Oct 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top